Filipe A Moura, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2026
Low-Dose CT as a Diagnostic Clue: Unmasking Anemia as a Cause of Reduced Myocardial Flow Reserve on PET/CT
Ambrosini A, Vashist A, Sinusas A, Moura F. Low-Dose CT as a Diagnostic Clue: Unmasking Anemia as a Cause of Reduced Myocardial Flow Reserve on PET/CT. Journal Of Nuclear Cardiology 2026, 102646. PMID: 41580018, DOI: 10.1016/j.nuclcard.2026.102646.Peer-Reviewed Original ResearchA Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes
Abel E, Ahima R, Anderson E, Berg D, Berger J, Das S, Feinberg M, Fisher E, Garshick M, Giannarelli C, Goldberg I, Hamburg N, Kim S, Moura F, Ndumele C, Newman J, Sabatine M, Selvin E, Shah R. A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes. Circulation Research 2026, 138: e325798. PMID: 41538415, DOI: 10.1161/circresaha.125.325798.Peer-Reviewed Original ResearchConceptsRisk of cardiovascular complicationsType 2 diabetesCardiovascular complicationsClinical studiesCardiometabolic healthCardiovascular diseaseAtherosclerotic cardiovascular diseaseAmerican Heart AssociationMedical therapyHeart failureWomen's HospitalHeart AssociationType II diabetesRisk factorsResearch NetworkDiabetesExperimental modelPrevention strategiesII diabetesComplicationsDiseaseType IHuman dataCardiometabolicRiskAssociation Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis.
Nogueira A, Rassi T, Iqbal A, Felix N, Alghaith O, Khan A, Rassi N, Maia M, Moura F. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis. Diabetes Care 2026 PMID: 41498755, DOI: 10.2337/dc25-1238.Peer-Reviewed Original ResearchNonarteritic ischemic optic neuropathyOdds ratioGLP-1 RA useIschemic optic neuropathyInverse-variance modelGLP-1Ocular eventsOptic neuropathyReceptor agonistsRA useAbsolute riskGLP-1 RA groupGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsRisk differenceGLP-1 receptor agonistsSecondary outcomesCochrane Library databasesOcular adverse eventsGLP-1 RAsMeta-analysisLongitudinal studyNonrandomized studiesLibrary databasesPostmarketing safety studies
2025
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
Marston N, Bergmark B, Alexander V, Prohaska T, Kang Y, Moura F, Zimerman A, Waldman E, Weinland J, Murphy S, Goodrich E, Zhang S, Xia S, Li D, Goldberg A, Goudev A, Badimon L, Kiss R, Vrablik M, Gaudet D, Moulin P, Stroes E, Banach M, Cohen H, Blom D, Charng M, Nordestgaard B, Nicholls S, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. The New England Journal Of Medicine 2025, 394: 429-441. PMID: 41211918, DOI: 10.1056/nejmoa2512761.Peer-Reviewed Original ResearchIncidence of acute pancreatitisSevere hypertriglyceridemiaTriglyceride levelsAcute pancreatitisApolipoprotein C-IIIPlacebo-adjusted least-squares mean changeRemnant cholesterolNon-high-density lipoprotein (non-HDL) cholesterolLeast-squares mean changeRisk of acute pancreatitisAcute pancreatitis eventPlacebo-adjusted changePlacebo-controlled trialHepatic fat fractionLiver enzyme levelsDose-dependent increaseNon-HDL cholesterolLevels of triglyceridesC-IIIPlacebo monthDouble-blindPancreatitis eventsPlacebo groupDose groupPancreatitis riskAntibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial
O’Donoghue M, Morrow D, Vavere A, Kardassis D, Moura F, Fagundes A, Ardissino D, Blaha V, Farkouh M, Kato E, Kimura T, Kiss R, Ophuis T, Selvanayagam J, Lopez-Sendon J, Wojakowski W, Zaman A, Lima J, Lu M, Foldyna B, Kuder J, Park J, Murphy S, Turton M, Collén A, Gabrielsen A, George R, Sabatine M. Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial. Nature Medicine 2025, 31: 3553-3559. PMID: 40999229, DOI: 10.1038/s41591-025-03951-w.Peer-Reviewed Original ResearchConceptsLectin-like oxidized low-density lipoprotein (LDL) receptor-1Residual inflammationSoluble LOX-1Plaque volumeMyocardial infarctionRate of serious adverse eventsNoncalcified coronary plaque volumeInterleukin-6Randomized phase 2 trialLow-attenuation plaque volumePlacebo-adjusted reductionsOxidized low-density lipoprotein cholesterolLow-density lipoprotein cholesterolCoronary plaque volumePhase 2 trialDose-finding studySerious adverse eventsComputed tomography angiographyLOX-1 inhibitionDiseased coronary segmentsDose armDouble-blindPlacebo groupExploratory endpointsPrimary endpointTargeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Kang Y, Weinland J, Murphy S, Goodrich E, Zhang S, Li D, Banach M, Stroes E, Lu M, Tsimikas S, Giugliano R, Sabatine M. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. The New England Journal Of Medicine 2025, 393: 1279-1291. PMID: 40888739, DOI: 10.1056/nejmoa2507227.Peer-Reviewed Original ResearchModerate hypertriglyceridemiaElevated cardiovascular riskTriglyceride levelsPlacebo-adjusted least-squares mean changeLeast-squares mean percent changesCardiovascular riskIncidence of serious adverse eventsLeast-squares mean changePlacebo-controlled trialBaseline to 6 monthsMedian triglyceride levelsSerious adverse eventsMessenger RNAApolipoprotein C-IIIDouble-blindPlacebo groupSevere hypertriglyceridemiaMedian ageDose groupAdverse eventsHypertriglyceridemiaTriglyceride clearancePrimary outcomeMean changePlaceboDetection of Hypertrophic Cardiomyopathy on Electrocardiogram Using Artificial Intelligence
Hillis J, Bizzo B, Mercaldo S, Ghatak A, MacDonald A, Halle M, Schultz A, L’Italien E, Tam V, Bart N, Moura F, Awad A, Bargiela D, Dagen S, Toland D, Blood A, Gross D, Jering K, Lopes M, Marston N, Nauffal V, Dreyer K, Scirica B, Ho C. Detection of Hypertrophic Cardiomyopathy on Electrocardiogram Using Artificial Intelligence. Circulation Heart Failure 2025, 18: e012667. PMID: 40365710, DOI: 10.1161/circheartfailure.124.012667.Peer-Reviewed Original ResearchHypertrophic cardiomyopathyDetection of hypertrophic cardiomyopathyAssociated with significant morbidityPredictive valueNegative predictive valueArea under the curvePositive predictive valueSudden cardiac deathSignificant morbidityChart reviewCardiac deathScreening electrocardiogramDiagnostic codesCardiac imagingClinical expertisePopulation prevalenceBinary outcomesCardiomyopathyElectrocardiogramDiagnosisImprove detectionPrevalenceElectrocardiogram featuresDISCOVERY AND VALIDATION OF PLASMA RENIN AND TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) AS CIRCULATING BIOMARKERS OF HEART FAILURE RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Berg D, Moura F, Bellavia A, Goodrich E, Scirica B, Wiviott S, Feinberg M, Morrow D, Sabatine M. DISCOVERY AND VALIDATION OF PLASMA RENIN AND TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) AS CIRCULATING BIOMARKERS OF HEART FAILURE RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal Of The American College Of Cardiology 2025, 85: 1528. DOI: 10.1016/s0735-1097(25)02012-1.Peer-Reviewed Original ResearchOlezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Kang Y, Murphy S, Zhang S, Lu M, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal 2025, 286: 116-124. PMID: 40081744, PMCID: PMC12065083, DOI: 10.1016/j.ahj.2025.02.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedApolipoprotein C-IIICardiovascular DiseasesClinical Trials, Phase III as TopicComputed Tomography AngiographyCoronary AngiographyDouble-Blind MethodFemaleHeart Disease Risk FactorsHumansHypertriglyceridemiaMaleMiddle AgedOligonucleotidesOligonucleotides, AntisenseRandomized Controlled Trials as TopicTriglyceridesConceptsCoronary Computed Tomography AngiographyCardiovascular riskTriglyceride levelsModerate hypertriglyceridemiaBaseline coronary computed tomography angiographyPlacebo-controlled phase 3 trialClearance of triglyceride-rich lipoproteinsApoC-IIIBaseline triglyceride levelsBaseline to 6 monthsLipid-Lowering TherapyAntisense oligonucleotidesNoncalcified coronary plaquesPhase 3 trialComputed tomography angiographyLowering triglyceride levelsIncreased cardiovascular riskElevated cardiovascular riskReduce cardiovascular riskAtherosclerotic cardiovascular diseaseTriglyceride-rich lipoproteinsPotential therapeutic strategyPooled placeboApolipoprotein C-IIIDouble-blindDesign and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia
Marston N, Bergmark B, Alexander V, Karwatowska-Prokopczuk E, Kang Y, Moura F, Prohaska T, Zimerman A, Zhang S, Murphy S, Tsimikas S, Giugliano R, Sabatine M. Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. American Heart Journal 2025, 286: 125-135. PMID: 40064331, PMCID: PMC12065585, DOI: 10.1016/j.ahj.2025.03.003.Peer-Reviewed Original ResearchConceptsSevere hypertriglyceridemiaAcute pancreatitis eventInvestigated antisense oligonucleotidesBaseline to 6 monthsPhase 3 trialTriglyceride-rich remnantsBaseline triglyceridesMatching placeboApolipoprotein C-IIIPancreatitis eventsMedian ageInhibit lipoprotein lipasePooled analysisClinical consequencesMRI substudyHypertriglyceridemiaSerum triglyceridesTG clearanceLife-threateningPatientsStudy populationApoC-IIIHepatic uptakeAntisense oligonucleotidesDedicated trials
Academic Achievements & Community Involvement
Teaching & Mentoring
Mentoring
Anderson Woite
Postgrad associate2025 - PresentJoaquim Barreto
Graduate student2025 - PresentAlleh Nogueira
Postgrad associate2024 - Present
News
News
Get In Touch
Contacts
Administrative Support
Events
May 20266Wednesday
Everyone Michael Fuery, MDMeeting ID: 956 3859 5269
May 202613Wednesday
Everyone Speakers to be announced.Meeting ID: 956 3859 5269
May 202620Wednesday
Everyone CancelledSpeakers to be announced.Meeting ID: 956 3859 5269
May 202627Wednesday
Everyone Speakers to be announced.Meeting ID: 956 3859 5269